Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
129.46
0.00 (0.00%)
Jul 17, 2025, 4:00 PM - Market closed
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 18 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $128.87, which forecasts a -0.46% decrease in the stock price over the next year. The lowest target is $105 and the highest is $138.
Price Target: $128.87 (-0.46%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 17, 2025.
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 4 | 4 |
| Buy | 7 | 8 | 8 | 8 | 2 | 1 |
| Hold | 5 | 6 | 6 | 6 | 14 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 19 | 22 | 21 | 21 | 20 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $143 → $129 | Buy → Hold | Downgrades | $143 → $129 | -0.36% | Jun 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $102 → $129 | Hold | Maintains | $102 → $129 | -0.36% | Jun 5, 2025 |
| UBS | UBS | Hold Maintains $88 → $129 | Hold | Maintains | $88 → $129 | -0.36% | Jun 5, 2025 |
| Citigroup | Citigroup | Strong Sell → Hold Upgrades $83 → $129 | Strong Sell → Hold | Upgrades | $83 → $129 | -0.36% | Jun 4, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 3, 2025 |
Financial Forecast
Revenue This Year
735.04M
from 508.82M
Increased by 44.46%
Revenue Next Year
975.99M
from 735.04M
Increased by 32.78%
EPS This Year
-0.91
from -1.07
EPS Next Year
0.99
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 811.7M | 1.1B | 1.4B | ||
| Avg | 735.0M | 976.0M | 1.2B | ||
| Low | 692.4M | 841.8M | 904.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.5% | 45.0% | 47.6% | ||
| Avg | 44.5% | 32.8% | 24.1% | ||
| Low | 36.1% | 14.5% | -7.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.24 | 3.22 | 7.85 | ||
| Avg | -0.91 | 0.99 | 4.23 | ||
| Low | -2.05 | -1.92 | 1.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 695.8% | ||
| Avg | - | - | 328.7% | ||
| Low | - | - | 57.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.